What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Beam Therapeutics Secures $500 Million Non-Dilutive Financing for Risto-cel Launch

Beam Therapeutics Inc. (Nasdaq: BEAM) has announced a strategic financing agreement worth up to $500 million with investment firm Sixth Street. The arrangement provides $100 million in immediate funding at closing, with an additional $400 million available through the facility. This non-dilutive capital is structured with a seven-year term, specifically designed to support the commercial launch of Risto-cel, a treatment for sickle cell disease. By securing this funding, the company strengthens its balance sheet without diluting existing shareholder equity. The move extends Beam's cash runway during a critical phase as it prepares for the anticipated market entry of its lead therapeutic candidate.

Beam Therapeutics Secures $500 Million Non-Dilutive Financing for Risto-cel Launch

Key Facts

Instruments